Search

Displaying results 3101 - 3110 of 10000 in total
  1. Drug

    Chromic chloride

    go.drugbank.com/drugs/DB09129
    Approved

    Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: ADDAMEL N 20 AMPUL, M T E 4 Concentrate InjCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Gastric intrinsic factor

    go.drugbank.com/drugs/DB09349
    Approved

    in the small intestine. … However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias

    Mixtures: EnLyte Extra-LN
  3. Drug

    Sinapic acid

    go.drugbank.com/drugs/DB08587
    Experimental

    Sinapic acid is a matrix for matrix-assisted laser desorption technique for protein MW determination. It is also a constituent of propolis.

    Synonyms: (E)-3-(4-Hydroxy-3,5-dimethoxyphenyl)-2-propenoic acidCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Nangibotide

    go.drugbank.com/drugs/DB16247
    Investigational

    Nangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).

  5. Drug

    MK-886

    go.drugbank.com/drugs/DB16739
    Experimental

    MK-886 is an experimental inhibitor of leukotriene synthesis.

  6. Drug

    MK-4965

    go.drugbank.com/drugs/DB08460
    Experimental

    MK-4965 is an HIV-1 reverse transcriptase inhibitor.

  7. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    [L45768] The most common type of non-Hodgkin lymphoma,[L45763] DLBCL is relatively sensitive to chemotherapy and generally responsive to first-line treatment regimens like CHOP ([cyclophosphamide], [doxorubicin … [L45768,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies -

  8. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting … RESP301 was also studied in a terminated trial (NCT05101915) for patients with mycobacterium abscesses and cystic fibrosis and in a completed trial with results (NCT04460183) for efficacy and safety in

  9. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    an invasive medical procedure [A36730]. … In September 2015, lusutrombopag received its first global approval in Japan to reduce the need for platelet transfusion in adults with chronic liver disease and thrombocytopenia who are schedule to undergo

  10. Drug

    Diclofenamide

    go.drugbank.com/drugs/DB01144
    Approved

    A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.

    Synonyms: 4,5-dichloro-m-benzenedisulfonamide